How a billionaire’s dream for a Florida railway went south
Brightline East, the brainchild of Wes Edens, is mired in complex debt negotiations
Comprehensive coverage of artificial intelligence and machine learning. Insights, analysis and opinions on how AI technology is shaping the future of business and finance.
Brightline East, the brainchild of Wes Edens, is mired in complex debt negotiations
AI lab’s advanced models escaped testing ‘sandbox’ to hack Hugging Face
Adam Candeub authored a Project 2025 chapter calling for a sweeping shake-up of US competition enforcement
505km per hour rail project has taken on symbolic importance
President chooses 43-year-old Mykhailo Drapatyi to replace Oleksandr Syrsky in generational shift in Kyiv’s military leadership
Disposal of Chinese agentic AI start-up has left the Facebook owner better off than it might seem
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Tim Bradshaw, Ashley Armstrong, Chris Smyth and Jim Pickard in London
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Your guide to what Trump’s second term means for Washington, business and the world
The UK utility company is investing $1.75bn in a developer focused on supplying power to data centres
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Pentagon says most soldiers suffered ‘minor concussions’ and have returned to duty
Trader nicknamed ‘Tommy Chocolate’ argues bank’s rate-fixing investigation was stacked against him
Riverstone is pioneering club-like housing schemes for asset-rich over-65s
My testy exchange outside a London pub with a self-proclaimed currency trading legend
Beijing consults companies on ways to stop west acquiring its advanced technologies and star start-ups
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
The US is on the verge of losing its status as the world’s leading agricultural exporter
US specialist venture firm Dimension Capital raises $800mn fund to back AI-designed medicines